US2014256620A1PendingUtilityA1

Methods for reducing cd36 expression

64
Assignee: SZETO HAZEL HPriority: Sep 16, 2005Filed: May 22, 2014Published: Sep 11, 2014
Est. expirySep 16, 2025(expired)· nominal 20-yr term from priority
A61P 3/10A61P 9/10A61P 43/00A61P 9/00A61P 3/06A61P 25/28A61P 29/00A61P 27/02A61P 3/04A61P 25/00A61P 13/12A61P 15/00A61P 13/02C07K 5/101A61K 38/06A61K 38/08A61K 38/00C07K 5/1016A61K 38/03C07K 5/1019A61K 48/00C07K 14/705C07K 5/1024A61K 38/07C07K 5/1008A61K 38/10
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3 p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.

Claims

exact text as granted — not AI-modified
1 .- 10 . (canceled) 
     
     
         11 . A method for treating tubular epithelial cell apoptosis in a subject in need thereof comprising administering to the subject an effective amount of an aromatic-cationic peptide having the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2  or Phe-D-Arg-Phe-Lys-NH 2  or a pharmaceutically acceptable salt thereof. 
     
     
         12 . The method of  claim 11 , wherein the peptide has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 . 
     
     
         13 . The method of  claim 11 , wherein the peptide has the formula Phe-D-Arg-Phe-Lys-NH 2 . 
     
     
         14 . The method of  claim 11 , wherein the subject is a human. 
     
     
         15 . The method of  claim 11 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly or transdermally. 
     
     
         16 . The method of  claim 11 , wherein the tubular epithelial cell apoptosis is associated with unilateral ureteral obstruction. 
     
     
         17 . The method of  claim 11 , wherein the method further treats interstitial fibrosis in the subject. 
     
     
         18 . The method of  claim 11 , wherein the method further reduces macrophage infiltration in the subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.